Despite remarkable pharmacological and medical scientific advancements, the pharma supply chain’s robustness has not advanced meaningfully.  It’s time to address the elephant in the room.

Opportunities arise from crises. It has never been more apparent than in this pandemic era that there are ways pharma companies and the industry can strengthen long-discussed supply chain vulnerabilities.

For years, the pharma industry and individual manufacturers alike have professed the need to improve the supply chain, and yet little transformative progress has been made. If the pandemic has not taught all of us the critical nature of pharma supply chain transformation, nothing will. But in order to get there, there are steps individual companies can take as well as considerations for the industry as a whole.